China, Guangzhou Prof. Yizhuo Zhang is a senior pediatric oncologist and internationally recognized expert in hematologic malignancies and pediatric cancers, based at Sun Yat-Sen University Cancer Center, China. She is a leading authority in hematopoietic stem cell therapy and translational oncology, with a distinguished career in advancing novel therapeutics, clinical trials, and precision medicine approaches in pediatric oncology and leukemia.
Current Position
- Professor, Department of Pediatric Oncology, Sun Yat-Sen University Cancer Center
Education
- MD, Nanjing Medical University
- Master’s & PhD in Hematology, Chinese PLA General Hospital
- Visiting Scholar, Pierre and Marie Curie University, France
- Clinical Visitor, MD Anderson Cancer Center, USA
- Clinical Visitor, Moffitt Cancer Center, USA
Areas of Specialization
- Pediatric oncology
- Hematologic malignancies
- Acute leukemia and malignant lymphoma
- Hematopoietic stem cell transplantation
- Translational oncology and drug development
- Precision oncology in pediatric cancers
Clinical & Research Focus
- Development of novel therapeutics for pediatric cancers
- Translational medicine in leukemia and lymphoma
- Molecular pathogenesis of hematologic malignancies
- Immunotherapy and targeted therapies in pediatric oncology
- Biomarker-driven treatment strategies and survival prediction models
Leadership & Clinical Trials
- Principal investigator and collaborator in 20+ national and international multicenter clinical trials
- Pioneer in early-phase and translational clinical trials for pediatric cancers in China
- Leader in implementing innovative therapeutic strategies in hematologic malignancies
- Active contributor to multidisciplinary pediatric oncology programs
Academic Profile
- Author of 150+ peer-reviewed publications
- 50+ publications indexed in SCI journals, including Leukemia
- Corresponding or first author on major studies in leukemia, lymphoma, and multiple myeloma
- Editorial Board Member, Chinese Journal of Clinical Oncology
- Editorial Board Member, Journal of Experimental Hematology
- Corresponding Editor, Chinese Journal of Hematology
Key Research Contributions
- Identified novel gene expression signatures predicting survival in diffuse large B-cell lymphoma
- Advanced research on exosome biology and therapeutic applications in multiple myeloma
- Investigated immune checkpoint pathways (PD-1/PD-L1) in malignant lymphomas
- Contributed to CAR-T cell therapy development for multiple myeloma
- Explored PI3K signaling pathways and molecular mechanisms in acute leukemia
- Studied viral oncogenesis, including Epstein-Barr virus in hematologic malignancies
- Developed predictive models for survival and toxicity in elderly multiple myeloma patients
Guidelines & Scientific Contribution
- Lead contributor to Chinese Society of Clinical Oncology (CSCO) Clinical Practice Guidelines in pediatric and adolescent lymphoma
- Contributor to national oncology guidelines and consensus statements
- Author of multiple book chapters including Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics
Professional Leadership
- Deputy Chairman, Blood Disease Translational Research Committee, Chinese Anti-Cancer Association
- Standing Committee Member, Hematological Tumor Committee, Chinese Anti-Cancer Association
- Deputy Team Leader, Pediatric and Adolescent Lymphoma Group, Chinese Society of Clinical Oncology (CSCO)
Innovation & Impact
- Leader in translational pediatric oncology bridging molecular research with clinical application
- Advanced development and clinical evaluation of novel targeted therapies
- Significant contributions to improving outcomes in leukemia and lymphoma
- Established international collaborations across Europe, North America, and Asia